

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
ELITRA.011AAPPLICATION NO.
09/815,242INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Haselbeck, et al.FILING DATE
March 21, 2001GROUP
1645 1635

MAY 16 2002

TECH CENTER 1600/2300

RECEIVED

COPY OF PAPERS
ORIGINALLY FILED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
29	1	4,622,297	11/11/86	Kappner, et al.			
	2	4,906,742	03/06/90	Young, et al.			
	3	4,980,281	12/25/90	Housey, et al.			
	4	5,082,767	01/21/92	Hatfield, et al.			
	5	5,142,047	08/25/92	Summerton, et al.			
	6	5,190,931	03/02/93	Inouye			
	7	5,208,149	05/04/93	Inouye, et al.			
	8	5,266,464	11/30/93	Housey, et al.			
	9	5,272,065	12/21/93	Inouye, et al.			
	10	5,353,236	10/04/94	Subbiah			
	11	5,405,775	04/11/95	Inouye, et al.			
	12	5,463,564	10/31/95	Agrafiotis, et al.			
	13	5,569,588	12/09/96	Ashby, et al.			
	14	5,574,656	11/12/96	Agrafiotis, et al.			
	15	5,585,277	12/17/96	Bowie, et al.			
	16	5,612,180	03/18/97	Brown, et al.			
	17	5,639,603	06/17/97	Dower, et al.			
	18	5,679,523	10/21/97	Li, et al.			
	19	5,684,711	11/04/97	Agrafiotis, et al.			
	20	5,688,655	11/08/97	Housey, et al.			
	21	5,744,460	04/28/98	Müller, et al.			
	22	5,756,305	05/26/98	Timberlake, et al.			
	23	5,807,522	09/15/98	Brown, et al.			
	24	5,821,076	10/13/98	Timberlake, et al.			
	25	5,846,772	12/08/98	Hodgson, et al.			
	26	5,854,020	12/29/98	Hodgson, et al.			
	27	5,858,709	01/12/99	Hodgson, et al.			
29	28	5,869,290	02/09/99	Freeman, et al.			

EXAMINER

DATE CONSIDERED

2/15/03

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.011AAPPLICATION NO.
09/815,242

RECEIVED

INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Haselbeck, et al.

MAY 15 2002

(USE SEVERAL SHEETS IF NECESSARY)

FILING DATE
March 21, 2001GROUP
1645

TECH CENTER 1800/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>SL</i>	29	5,869,604	02/09/99	Rousseau, et al.			
	30	5,877,007	03/02/99	Housey, et al.			
	31	5,882,643	03/16/99	Lonetto			
	32	5,885,572	03/23/99	Gentry, et al.			
	33	5,891,667	04/06/99	Hodgson, et al.			
	34	5,910,414	06/08/99	Gwynn, et al.			
	35	5,955,275	09/21/99	Kamb			
	36	5,965,352	10/12/99	Stoughton, et al.			
	37	5,972,708	10/26/99	Sherratt, et al.			
	38	6,015,669	01/18/00	Holden			
	39	6,020,121	02/01/00	Bao, et al.			
	40	6,037,123	03/14/00	Benton, et al.			
	41	6,077,682	06/20/00	Inouye, et al.			
	42	6,139,817	10/31/00	Palmer, et al.			
	43	6,156,526	12/05/02	Boriack-Sjodin, et al.			
	44	6,174,678 B1	01/16/01	Menzel, et al.			
	45	6,248,525 B1	06/19/01	Nilsen			
	46	6,277,564	08/21/01	Berlin, et al.			
	47	6,303,115 B1	10/16/01	Natsoulis			
	48	6,348,582 B1	02/19/02	Black, et al.			
<i>SL</i>	49	6,348,582	02/19/02	Black, et al. (Printout of Sequence Listing)			

COPY OF PAPERS
ORIGINALLY FILED

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>SL</i>	50	EP 0 786 519 A2	07/30/97	EPO				
	51	EP 0 786 519 A3	07/30/97	EPO				
	52	EP 0 816 511 A1	01/07/98	EPO				
<i>SL</i>	53	EP 0 837 142 A1	04/22/98	EPO				

EXAMINER

SL

DATE CONSIDERED

9/15/03

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.011AAPPLICATION NO.
09/815,242

RECEIVED

INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Haselbeck, et al.

MAY 16 2002

(USE SEVERAL SHEETS IF NECESSARY)

FILING DATE
March 21, 2001GROUP
1645

TECH CENTER 1600/2000

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>JS</i>	54	EP 0 889 123 A2	01/07/99	EPO				
	55	EP 0 889 129 A2	01/07/99	EPO				
	56	EP 0 891 984 A2	01/20/99	EPO				
	57	EP 0 892 056 A2	01/20/99	EPO				
	58	EP 0 892 064 A2	01/20/99	EPO				
	59	EP 0 894 806 A1	02/03/99	EPO				
	60	EP 0 897 008 A2	02/17/99	EPO				
	61	EP 0 900 845 A2	03/10/99	EPO				
	62	EP 0 905 247 A2	03/31/99	EPO				
	63	EP 0 906 959 A2	04/07/99	EPO				
	64	WO 95/02823	01/26/95	PCT				
	65	WO 95/06132	03/02/95	PCT				
	66	WO 96/17951	06/13/96	PCT				
	67	WO 96/23075	08/01/96	PCT				
	68	WO 96/40979	12/19/96	PCT				
	69	WO 97/11690	04/03/97	PCT				
	70	WO 97/16177	05/09/97	PCT				
	71	WO 97/23642	07/03/97	PCT				
	72	WO 97/27212	07/31/97	PCT				
	73	WO 97/27213	07/31/97	PCT				
	74	WO 97/37026	10/09/97	PCT				
	75	WO 97/40851	11/06/97	PCT				
	76	WO 97/42210	11/13/97	PCT				
	77	WO 97/48822	12/24/97	PCT				
	78	WO 98/03533	01/29/98	PCT				
	79	WO 98/19162	05/07/98	PCT				
	80	WO 98/20161	05/14/98	PCT				
<i>JS</i>	81	WO 98/21366	05/22/98	PCT				

COPY OF PAPERS
ORIGINALLY FILED

EXAMINER

DATE CONSIDERED

9/15/03

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.011AAPPLICATION NO.
09/815,242

RECEIVED

INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Haselbeck, et al.

MAY 16 2002

(USE SEVERAL SHEETS IF NECESSARY)

FILING DATE
March 21, 2001GROUP
1645

1635 - ENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
LS	82	WO 98/42854	10/01/98	PCT				
	83	WO 98/44135	10/08/98	PCT				
	84	WO 98/50555	11/12/98	PCT				
	85	WO 99/02673	01/21/99	PCT				
	86	WO 99/06839	02/11/99	PCT				
	87	WO 99/13893	03/25/99	PCT				
	88	WO 99/23244	05/14/99	PCT				
	89	WO 99/26651	06/03/99	PCT				
	90	WO 99/27074	06/03/99	PCT				
	91	WO 99/27128	06/03/99	PCT				
	92	WO 99/28508	06/10/99	PCT				
	93	WO 99/29837	06/17/99	PCT				
	94	WO 99/33871	07/08/99	PCT				
	95	WO 99/35494	07/15/99	PCT				
	96	WO 99/36554	07/22/99	PCT				
	97	WO 99/43338	09/02/99	PCT				
	98	WO 99/49888	10/07/99	PCT				
	99	WO 99/50462	10/07/99	PCT				
	100	WO 99/52926	10/21/99	PCT				
	101	WO 99/53079	10/21/99	PCT				
	102	WO 99/54728	10/28/99	PCT				
	103	WO 99/55729	11/04/99	PCT				
	104	WO 99/61452	12/02/99	PCT				
	105	WO 00/34481	06/15/00	PCT				
	106	WO 00/61793	10/19/00	PCT				
	107	WO 01/09164 A2	02/08/01	PCT				
	108	WO 01/11081 A2	02/15/01	PCT				
AK	109	WO 01/34809 A2	05/17/01	PCT				

COPY OF PAPER
ORIGINALLY FILED

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.011AAPPLICATION NO.
09/815,242

RECEIVED

INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Haselbeck, et al

MAY 16 2002

(USE SEVERAL SHEETS IF NECESSARY)

FILING DATE
March 21, 2001GROUP
1645

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	110	WO 01/49721 A2	07/12/01	PCT				
	111	WO 01/49775 A2	07/12/01	PCT				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
LL	112	Akerley, et al. "A genome-scale analysis for identification of genes required for growth or survival of <i>Haemophilus influenzae</i> ," <i>PNAS</i> , 99(2):966-971 (2002).
	113	Almarsson, et al. 1993. Peptide nucleic acid (PNA) conformation and polymorphism in PNA-DNA and PNA-RNA hybrids. <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 90:9542-9546.
	114	Altschul, et al. 1990. Basic local alignment search tool. <i>J. Mol. Biol.</i> , 215:403-10.
	115	Altschul, et al. 1997. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. <i>Nucleic Acid Res.</i> , 25(17): 3389-3402.
	116	Appelt, K. 1993. Crystal structures of HIV-1 protease-inhibitor complexes. <i>Perspectives in Drug Discovery and Design</i> , 1:23-48.
	117	Arigoni, et al. 1998. A genome-based approach for the identification of essential bacterial genes. <i>Nature Biotechnology</i> , 16:851-856.
	118	Armstrong, et al. (1975), Essential Genes in the <i>metB-malB</i> Region of <i>Escherichia coli</i> K12, <i>J. Bacteriol.</i> , 126:48-55.
	119	Austin, et al. 1990. Genetic Analysis of Lipopolysaccharide Core Biosynthesis by <i>Escherichia coli</i> k12 Insertion Mutagenesis of the RFA Locus. <i>Journal of Bacteriology</i> , 172:5312-5325.
	120	Ausubel, et al. (Eds.). 1997. Current Protocols in Molecular Biology, Vol. 1, Unit 1.8.1-1.8.10. John Wiley & Sons, Inc.
	121	Bagby, et al. 1994. Unusual helix-containing Greek keys in development-specific Ca ²⁺ -binding protein S. ¹ H, ¹⁵ N, and ¹³ C assignments and secondary structure determined with the use of multidimensional double and triple resonance heteronuclear NMR spectroscopy. <i>Biochemistry</i> , 33:2409-2421.
	122	Bagby, et al. 1995. Solution structure of the C-terminal core domain of human TFIIIB: Similarity to Cyclin A and interaction with TATA-binding protein. <i>Cell</i> , 82:857-867.
	123	Balbes, et al. 1994. "A perspective of modern methods in computer-aided drug design." In Lipkowitz, et al., Eds. <i>Reviews in Computational Chemistry V</i> . Chap. 7, pp. 337-379. New York: VCH Publishers.
	124	Basu, et al. 1997. Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. <i>Bioconjugate Chem.</i> , 8:481-488.
	125	Bentin, et al. 1996. Enhanced peptide nucleic acid binding to supercoiled DNA: Possible implications for DNA "breathing" dynamics. <i>Biochemistry</i> , 35:8863-8869.
	126	Biswas, et al. 1999. Mechanism and DnaB Helicase of <i>Escherichia coli</i> : Structural Domains Involved in ATP Hydrolysis, DNA Binding, and Oligomerization. <i>Biochem.</i> , 38:10919-10928.
	127	Blattner, et al. 1997. The Complete Genome Sequence of <i>Escherichia Coli</i> K-12. <i>Science</i> , 277:1453-1474.
	128	Blattner, et al. <i>Escherichia coli</i> K12 MG1655 section 337 of 400 of the complete genome. Database accession no. AE000447, XP002181127.
	129	Blattner, et al. <i>Escherichia coli</i> K12 MG1655 section 298 of 400 of the complete genome. Database accession no. AE000408, XP002181129.
	130	Blattner, et al. <i>Escherichia coli</i> K12 MG1655 section 101 of 400 of the complete genome. Database accession no. AE000211, XP002181472.
	131	Blattner, et al. <i>Escherichia coli</i> K12 MG1655 section 305 of 400 of the complete genome. Database accession no. AE000415, XP002181474.
	132	Blattner, et al. Hypothetical 79.5 kDa protein in MRCA-PCKA intergenic region (0711). Database accession no. P45800, XP002181475.
	133	Blattner, et al. Hypothetical protein YCFS precursor. Database accession no. P75954, XP002181473.
	134	Brenner, et al. 2000. <i>Salmonella</i> nomenclature. <i>Journal of Clinical Microbiology</i> , 38(7):2465-2467.
LL	135	Brunschwig, et al. 1992. A two-component T7 system for the overexpression of genes in <i>Pseudomonas aeruginosa</i> . <i>Gene</i> , 111:35-41.

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

COPY OF PAPERS
ORIGINALLY FILED

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.011AAPPLICATION NO.
09/815,242

RECEIVED

INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Haselbeck, et al.FILING DATE
March 21, 2001GROUP
1635

MAY 16 2002

CENTER 1600/2900

(USE SEVERAL SHEETS IF NECESSARY)

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

- 136 Bugg, et al. 1993. Drugs by design: Structure-based design, an innovative approach to developing drugs, has recently spawned many promising therapeutic agents, including several now inhuman trials for treating AIDS, cancer and other diseases. *Scientific American*, Dec.:92-98.
- 137 Burland, et al. "60 kDa inner-membrane protein." Database accession no. P25714, XP002181128.
- 138 Burland, et al. E. coli; the region from 81.5 to 84.5 minutes. Database accession no. L10328, XP002181130.
- 139 Burland, et al. 1993. DNA sequence and analysis of 136 kilobases of the *Escherichia coli* genome: Organizational symmetry around the origin of replication. *Genomics*, 16:551-561.
- 140 Cao, et al. 1993. Expression and functional analysis of steroid receptor fragments secreted from *Staphylococcus aureus*. *J. Steroid Biochem Molec. Biol.*, 44(1):1-11.
- 141 Ceretti, et al. *Escherichia coli* spc ribosomal protein operon. Database accession no. X01563, XP002181131.
- 142 Clore, et al. 1987. Three-dimensional structure of potato carboxypeptidase inhibitor in solution: A study using nuclear magnetic resonance, distance geometry, and restrained molecular dynamics. *Biochemistry*, 26:8012-8023.
- 143 Cotrim, et al. 1999. Isolation of Genes Mediating Resistance to Inhibitors of Nucleoside and Ergosterol Metabolism in *Leishmania* by Overexpression/Selection. *Journal of Biological Chemistry*, 274(53):37723-37730.
- 144 Crosa, et al. 1973. Molecular relationships among the Salmonellae. *J. Bacteriol.*, 115(1):307-315.
- 145 Cwirla, et al. 1990. Peptides on phage: A vast library of peptides for identifying ligands. *Proc. Natl. Acad. Sci. USA*, 87:6378-6382.
- 146 De Backer, et al. 2001. An antisense-based functional genomics approach for identification of genes critical for growth of *Candida albicans*. *Nature Biotechnology*, 19:235-241.
- 147 Demidov, et al. 1995. Kinetics and mechanism of polyamide ("peptide") nucleic acid binding to duplex DNA. *Proc. Natl. Acad. Sci. U.S.A.*, 92:2637-2641.
- 148 Demidov, et al. 1993. Sequence selective double strand DNA cleavage by Peptide Nucleic Acid (PNA) targeting using nuclease S1. *Nucl. Acids. Res.*, 21(9):2103-2107.
- 149 Demidov, et al. 1994. Stability of peptide nucleic acids in human serum and cellular extracts. *Biochem. Pharm.*, 48(6):1010-1313.
- 150 den Hollander, J.G., et al. 1997. Synergism Between Tobramycin and Ceftazidime Against a Resistant *Pseudomonas Aeruginosa* Strain, Tested in an In Vitro Pharmacokinetic Model. *Antimicrobia Agents & Chemotherapy*, 41:95-110.
- 151 Devlin, et al. 1990. Random peptide libraries: A source of specific protein binding molecules. *Science*, 249:404-406.
- 152 Edwards, B. H. 1999. *Salmonella* and *Shigella* species. *Clinics Lab. Med.*, 19(3):469-487.
- 153 Egholm, et al. 1995. Efficient pH-independent sequence-specific DNA binding by pseudoisocytosine-containing bis-PNA. *Nucleic Acids Res.*, 23(2):217-222.
- 154 Egholm, et al. 1993. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. *Nature*, 365:566-568.
- 155 Egholm, et al. 1992. Recognition of Guanine and Adenine in DNA by Cytosine and Thymine Containing Peptide Nucleic Acids (PNA). *J. Am. Chem. Soc.*, 114(24):9677-9678.
- 156 Engvall, E. 1980. Enzyme Immunoassay ELISA and EMIT. *Meth. Enzymol.*, 70:419-439.
- 157 Erickson, J. W. 1993. Design and structure of symmetry-based inhibitors of HIV-1 protease. *Perspectives in Drug Discovery and Design*, 1:109-128.
- 158 Etzold, et al. 1993. Sequence Retrieval System (SRS). SRS An indexing and retrieval tool for flat file data libraries. *Comput. Appl. Biosci.* 9(1):49-57.
- 159 Fukuoka, et al. 1997. Combination Effect Between Panipenem and Vancomycin on Highly Methicillin-Resistant *Staphylococcus Aureus*. *Japan. J. Antibio.*, 50:411-419.
- 160 Gabryelewicz, et al. 1997. Multicenter Evaluation of Dual-Therapy (Omeprazol and Amoxycillin) for *Helicobacter Pylori*-Associated Duodenal and Gastric Ulcer (Two Years of the Observation). *J. Physiol. Pharmacol.*, 48 Suppl. 4:93-105.
- 161 Gallop, et al. 1994. Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries. *Journal of Medicinal Chemistry*, 37(9):1233-1251.
- 162 Good, et al. 1998. Antisense inhibition of gene expression in bacteria by PNA targeted to mRNA. *Nature Biotechnology*, 16:355-358.
- 163 Griffin, et al. 1989. Recognition of Thymine Adenine Base Pairs by Guanine in a Pyrimidine Triple Helix Motif. *Science*, 245:967-971.
- 164 Griffith, et al. 1995. Single and bis peptide nucleic acids as triplexing agents: Binding and Stoichiometry. *J. Am. Chem. Soc.*, 117:831-832.
- 165 Gudkov, et al. "Isolation of Genetic Suppressor Elements (GSEs) from Random Fragment cDNA Libraries in Retroviral Vectors." In Cowell, et al. (Eds.), *Methods in Molec. Biol.*, Vol. 69 cDNA Library Protocols, Totowa, NY: Humana Press, Inc.

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.011AAPPLICATION NO.
09/815,242

RECEIVED

INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Haselbeck, et al.

MAY 16 2002

FILING DATE
March 21, 2001GROUP
1945

1635 TECH CENTER 1600/290

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

166	Gutmann, et al. 1986. Involvement of Pencillin-Binding Protein 2 with other Pencillin-Binding Proteins in Lysis of <i>Escherichia coli</i> by some Beta-Lactam Antibiotics Alone and in Synergistic Lytic Effect of Amdinocillin (Mecillinam). <i>Antimicrobial Agents & Chemotherapy</i> , 30:906-912.
167	Hamilton, et al. 1989. New method for generating deletions and gene replacements in <i>Escherichia coli</i> . <i>J. Bacteriol.</i> , 171(9):4617-4622.
168	Hanvey, et al. 1992. Antisense and antigene properties of peptide nucleic acids. <i>Science</i> , 258:1481-1484.
169	Hare, et al. 2001. Genetic footprinting in bacteria. <i>J. Bacteriol.</i> , 183(5):1694-1706.
170	Hensel, et al. 1995. Simultaneous identification of bacterial virulence genes by negative selection. <i>Science</i> , 269:400-403.
171	Hiasa, et al. 1999. Initiation of Bidirectional Replication at the Chromosomal Origin is Directed by the Interaction Between Helicase and primase. <i>J. Biol. Chem.</i> , 274:27244-27248.
172	Hirschman, et al. 1996. Peptide nucleic acids stimulate gamma interferon and inhibit the replication of the human immunodeficiency virus. <i>J. Invest. Med.</i> , 44(6):347-351.
173	Ho, et al. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. <i>Gene</i> , 77:51-59.
174	Holzmayr, et al. 1992. Isolation of Dominant Negative Mutants and Inhibitory Antisense RNA Sequences by Expression Selection of Random DNA Fragments. <i>Nucleic Acids Res.</i> , 20(4):711-717.
175	Horton, et al. 1989. Engineering hybrid genes without the use of restriction enzymes: Gene splicing by overlap extension. <i>Gene</i> , 77:61-68.
176	Huerta, et al. 1998. RegulonDB: A database on transcriptional regulation in <i>Escherichia coli</i> . <i>Nucl. Acids Res.</i> , 26(1):55-59.
177	Huycke, et al. 1998. Multiple-drug resistant enterococci: The nature of the problem and an agenda for the future. <i>Emerging Infectious Diseases</i> , 4(2):239-249.
178	Israelsen, et al. 1995. Cloning and partial characterization of regulated promoters from <i>Lactococcus lactis</i> Tn917-lacZ integrants with the new promoter probe vector, pAK80. <i>Applied and Environmental Microbiology</i> , 61(7):2540-2547.
179	Ji, et al. 1999. Regulated Antisense RNA Eliminates Alpha-Toxin Virulence in <i>Staphylococcus Aureus</i> Infection. <i>J. Bacteriology</i> , 181(21):6585-6590.
180	Kohler, et al. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. <i>Nature</i> , 256:495-497.
181	Krause, et al. 1997. Complexes at the replication origin of <i>Bacillus subtilis</i> with homologous and heterologous dnaA protein. <i>J. Mol. Biol.</i> , 274:365-380.
182	Kreiswirth, et al. 1983. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. <i>Nature</i> , 305:709-712.
183	Lam, et al. 1994. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. <i>Science</i> , 263:380-384.
184	Lancy, et al. 1989. Nucleotide Sequences of dnaE, the Gene for the Polymerase Subunit of DNA Polymerase III in <i>Salmonella typhimurium</i> , and a Variant That Facilitates Growth in the Absence of Another Polymerase Subunit. <i>Journal of Bacteriology</i> , 171(10):5581-5586.
185	Le Good, et al. 1998. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. <i>Science</i> , 281:2042-2045.
186	Leboeuf, et al. 2000. Characterization of the ccpA gene of <i>Enterococcus faecalis</i> : Identification of starvation-inducible proteins regulated by CcpA. <i>J. Bacteriology</i> , 182(20):5799-5806.
187	Lee, et al. 1995. Molecular Cloning and Characterization of the Nontypable Haemophilus Influenzae-2019 rfaE Gene Required for Lipopolysaccharide Biosynthesis. <i>Infection and Immunity</i> , 63(3):818-824.
188	Link, et al. 1997. Methods for Generating Precise Deletions and Insertions in the Genome of Wild-Type <i>Escherichia coli</i> : Application to Open Reading Frame Characterization. <i>J. Bacteriol.</i> , 179(20):6228-6237.
189	Margolis, et al. 2000. Peptide Deformylase in <i>Staphylococcus aureus</i> : Resistance to Inhibition Is Mediated by Mutations in the Formyltransferase Gene. <i>Infection and Immunity</i> , 63(3):818-824.
190	Marrone, et al. 2000. Discovering high-affinity ligands from the computationally predicted structures and affinities of small molecules bound to a target: A virtual screening approach. <i>Perspectives in Drug Discovery and Design</i> , 20:209-230.
191	Matsukura, et al. 1988. Synthesis of phosphorothioate analogues of oligodeoxynucleotides and their antiviral activity against human immunodeficiency virus (HIV). <i>Gene</i> , 72:343.
192	Mestres, et al. 2000. Similarity versus docking in 3D virtual screening. <i>Perspectives in Drug Discovery and Design</i> , 20:191-207.
193	Mojumdar, et al. 1988. Characterization of the tetracycline resistance gene of plasmid pT181 of <i>Staphylococcus aureus</i> . <i>J. Bacteriology</i> , 170(12):5522-5528.
194	Mollegaard, et al. 1994. Peptide nucleic acid DNA strand displacement loops as artificial transcription promoters. <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 91:3892-3895.
195	Morrissey, et al. 2000. Molecular Cloning and Analysis of a Putative Siderophore ABC Transporter from <i>Staphylococcus aureus</i> . <i>Infection and Immunity</i> , 68(11):6281-6288.

EXAMINER

Lisa J. Hill

DATE CONSIDERED

9/15/03

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

COPY OF PAPERS
ORIGINALY FILED

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.011AAPPLICATION NO.
09/815,242

RECEIVED

INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Haselbeck, et al.FILING DATE
March 21, 2001GROUP
1645

(USE SEVERAL SHEETS IF NECESSARY)

MAY 16 2002

TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
196	Moszer, et al. 1995. <i>SubtilList</i> : A relational database for the <i>Bacillus subtilis</i> genome. <i>Microbiology</i> , 141:261-268.	
197	Moszer, I. 1998. The complete genome of <i>Bacillus subtilis</i> : From sequence annotation to data management and analysis. <i>FEBS Letters</i> , 430:28-36.	
198	Nallapareddy, et al. 2000. <i>Enterococcus faecalis</i> adhesin, ace, mediates attachment to extracellular matrix proteins collagen type IV and laminin as well as collagen type I. <i>Infect. Immun.</i> , 68(9):5218-5224.	
199	Neidhardt, F. C. (Ed.). 1996. <i>Escherichia coli</i> and <i>Salmonella</i> : Cellular and molecular biology, 2nd Ed., Vol. 2, pp. 2269-2271. Washington, D.C.: ASM Press.	
200	Nielsen, et al. 1991. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. <i>Science</i> , 254:1497-1500.	
201	Nielsen, et al. 1993. Sequence specific inhibition of DNA restriction enzyme cleavage by PNA. <i>Nucl. Acids. Res.</i> , 21(2):197-200.	
202	Nielsen, et al. 1994. Sequence-specific transcription arrest by peptide nucleic acid bound to the DNA template strand. <i>Gene</i> , 149:139-145.	
203	Norton, et al. 1996. Inhibition of human telomerase activity by peptide nucleic acids. <i>Nature Biotechnol.</i> , 14:615-619.	
204	Oshima, et al. 1996. A 718-kb DNA Sequence of the <i>Escherichia coli</i> K-12 Genome Corresponding to the 12.7-28.0 min Region on the Linkage Map. <i>DNA Research</i> , 3:137-155.	
205	Oshima, et al. 1996. <i>Escherichia coli</i> genomic DNA (25.2-25.6 min). Database accession no. D90747, XP002181476.	
206	Pardridge, et al. 1995. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> . <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 92:5592-5596.	
207	Pearson, W. R. 1990. Rapid and sensitive sequence comparison with FASTP and FASTA. <i>Methods in Enzymology</i> , 183:63-98.	
208	Plá, et al. 1990. Cloning and expression of the <i>ponB</i> gene, encoding penicillin-binding protein 1B of <i>Escherichia coli</i> , in heterologous systems. <i>J. Bacteriol.</i> , 172(8):4448-4455.	
209	Plunkett, et al. <i>Escherichia coli</i> K-12 chromosomal region from 67.4 to 76.0 minutes. Database accession no. U18997, XP002181132.	
210	Plunkett, et al. <i>Escherichia coli</i> K-12 chromosomal region from 67.4 to 76.0 minutes. Database accession no. U18997, XP002181477.	
211	Post, et al. 1979. Nucleotide Sequence of the Ribosomal Protein Gene Cluster Adjacent to the Gene for RNA Polymerase Subunit Beta in <i>Escherichia Coli</i> . <i>Proceedings of the National Academy of Sciences of the USA</i> , 76(4):1697-1701.	
212	Rossi, et al. 1991. The potential use of catalytic RNAs in therapy of HIV infection and other diseases. <i>Pharmac. Ther.</i> , 50:245-254.	
213	Rudd, K. E. 1998. Linkage map of <i>Escherichia coli</i> K-12, edition 10: The physical map. <i>Micro. & Mol. Biol. Rev.</i> , 62(3):985-1019.	
214	San Martin, et al. 1998. Three-Dimensional Reconstructions from Cryoelectron Microscopy Images Reveal an Intimate Complex Between Helicase DnaB and its Loading Partner DnaC. <i>Structure</i> , 6:501-9.	
215	Schena, et al. 1995. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. <i>Science</i> , 270:467-470.	
216	Schnappinger, et al. 1995. Extracellular expression of native human anti-lysozyme fragments in <i>Staphylococcus carnosus</i> . <i>FEMS Microbiol. Lett.</i> , 129:121-127.	
217	Scott, et al. 1990. Searching for peptide ligands with an epitope library. <i>Science</i> , 249:386-390.	
218	Shalon, et al. 1996. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. <i>Genome Research</i> , 6:639-645.	
219	Shuker, et al. 1996. Discovering high-affinity ligands for proteins: SAR by NMR. <i>Science</i> , 274:1531-1534.	
220	Smith, et al. 1997. Assessment of the Synergistic Interactions of Levofloxacin and Ampicillin Against <i>Enterococcus Faecium</i> by the Checkerboard Agar Dilution and Time-Kill Methods. <i>Diagnos. Microbiol. Infect. Disease</i> , 27:85-92.	
221	Suh, et al. 1995. Genetic and transcriptional organization of the <i>Bacillus subtilis</i> <i>spc-alpha</i> region. Database accession no. L47971 (ID: BSRPLP), XP002190118.	
222	Suh, et al. 1996. Genetic and transcriptional organization of the <i>Bacillus subtilis</i> <i>spc-alpha</i> region. <i>Gene</i> , 169:17-23.	
223	Sutton, et al. 1998. <i>Escherichia coli</i> DnaA Protein. The N-Terminal Domain and Loading of DnaB Helicase at the <i>E. coli</i> Chromosomal. <i>J. Biol. Chem.</i> , 273:34255-62.	
224	Tao, et al. 2000. Drug target validation: Lethal infection blocked by inducible peptide. <i>PNAS</i> , 97(2):783-786.	
225	Tatusov, et al. 2000. The COG database: A tool for genome-scale analysis of protein functions and evolution. <i>Nucleic Acids Research</i> , 28(1):33-36.	

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

COPY OF PAPERS
ORIGINAL FILED

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.011AAPPLICATION NO.
09/815,242INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Haselbeck, et al.FILING DATE
March 21, 2001GROUP
1645

RECEIVED

MAY 16 2002

TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
Set	226	Uhlmann, et al. 1990. Antisense Oligonucleotides: A New Therapeutic Principle. <i>Chemical Reviews</i> , 90(4):543-584.
	227	Vaitukaitis, et al. 1971. A method for producing specific antisera with small doses of immunogen. <i>J. Clin. Endocr. Metab.</i> , 33:988-991.
	228	Valvano, et al. 2000. The rfaE Gene from <i>Escherichia coli</i> Encodes a Bifunctional Protein Involved. <i>Journal of Bacteriology</i> , 182:488-497.
	229	Van Delden, et al. 1998. Cell-to-cell signaling and <i>Pseudomonas aeruginosa</i> infections. <i>Emerging Infectious Diseases</i> , 4(4):551-560.
	230	Van Heeswijk, et al. 1993. The Genes of the Glutamine Synthetase Adenylylation Cascade are not Regulated by Nitrogen in <i>Escherichia coli</i> . <i>Molecular Microbiology</i> , 9:443-457.
	231	Wagner, et al. 1987. Protein structures in solution by nuclear magnetic resonance and distance geometry: The polypeptide fold of the basic pancreatic trypsin inhibitor determined using two different algorithms, DISGEO and DISMAN. <i>J. Mol. Biol.</i> , 196:611-639.
	232	Wallis, et al. 2000. Molecular basis of <i>Salmonella</i> -induced enteritis. <i>Molec. Microb.</i> , 36(5):997-1005.
	233	Wechsler, et al. 1971. <i>Escherichia coli</i> Mutants Temperature-Sensitive for DNA Synthesis. <i>Mol. Gen. Genetics</i> , 113:273-284.
	234	Wlodawer, et al. 1993. Structure-based inhibitors of HIV-1 protease. <i>Annu. Rev. Biochem.</i> , 62:543-585.
	235	Wong, et al. 2000. Genetic footprinting with <i>mariner</i> -based transposition in <i>Pseudomonas aeruginosa</i> . <i>PNAS</i> , 97(18):10191-10196.
	236	Wüthrich, et al. 1983. Pseudo-structures for the 20 common amino acids for use in studies of protein conformations by measurements of intramolecular proton-proton distance constraints with nuclear magnetic resonance. <i>J. Mol. Biol.</i> , 169:949-961.
	237	Xia, et al. 1999. Rapid method for the identification of essential genes in <i>Staphylococcus aureus</i> . <i>Plasmid</i> , 42:144-149.
	238	Zhang, et al. 2000. Regulated Gene Expression in <i>Staphylococcus aureus</i> for Identifying Conditional Lethal Phenotypes and Antibiotic Mode of Action. <i>Gene</i> , 255:297-305.
	239	Zhang, et al. 1996. Polar Allele Duplication for Transcriptional analysis of consecutive essential genes: Application to a cluster of <i>Escherichia coli</i> fatty acid biosynthetic genes. <i>J. Bacteriol.</i> , 178(12):3614-3620.
Ly	240	European Search Report from co-pending Application No. PCT/US01/09180.

S:\DOCS\DOH\DOH-6518.DOC:dmb
030302COPY OF PAPERS
ORIGINALLY FILED

EXAMINER <i>Line Hill</i>	DATE CONSIDERED <i>9/15/03</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.011AAPPLICATION NO.
09/852,412SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Haselbeck, et al.FILING DATE
March 21, 2001GROUP
1635

1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>SK</i>	1	6,228,579 B1	05/08/01	Zyskind, et al.			
<i>SH</i>	2	6,228,588 B1	05/08/01	Benton, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL		
<i>SK</i>	3	Good, et al. 1998. Inhibition of translation and bacterial growth by peptide nucleic acid targeted to ribosomal RNA. <i>Proc. Natl. Acad. Sci. USA</i> , 95:2073-2076.

S:\DOCS\DOH\DOH-6829.DOC:dmb
062402

EXAMINER

Due Hill

DATE CONSIDERED

9/15/03

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.011AAPPLICATION NO.
09/815,242SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Haselbeck, et al.FILING DATE
March 21, 2001GROUP
1635

RECEIVED

SEP 12 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>SL</i>	1	US 2002/0058260 A1	05/16/02	Zyskind, et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>SL</i>	2	WO 02/16940 A2	02/28/02	PCT				

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

S:\DOCS\DOH\DOH-6986.DOC:dmb
090302

EXAMINER

Rua

DATE CONSIDERED

9/15/03

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.011AAPPLICATION NO.
09/815,242SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Haselbeck, et al.FILING DATE
March 21, 2001GROUP
1631

RECEIVED

OCT 11 2002

USE SEVERAL SHEETS IF NECESSARY)

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>Ed</i>	1	5,874,281	02/23/99	Dattagupta, et al.			
<i>Ed</i>	2	5,874,567	02/23/99	Smith			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>Ed</i>	3	WO 95/29254	11/02/95	PCT				

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

S:\DOCS\DOH\DOH-7090.DOC:dmb
100402

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ELITRA.011AAPPLICATION NO.
09/815,242SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Haselbeck, et al.FILING DATE
March 21, 2001GROUP
1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)


RECEIVED

AUG 01 2003


TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO


EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1	Hwang, et al. 2001. An essential GTPase, Der, containing doublet GTP-binding domains from Escherichia coli and Thermotoga maritima. The Journal of Biological Chemistry, 276:33:31415-31421.
	2	Mehr, et al. 2000. A homologue of the recombination-dependent growth gene, rdgC, is involved in gonococcal pilin antigenic variation. Genetics, 154:523-532.

S:\DOCS\DOH\DOH-7562.DOC:dmb
072903

EXAMINER 	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

#15

RECEIVED



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ELITRA.011A	APPLICATION NO. 09/815,242
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Haselbeck, et al.
FILING DATE March 21, 2001		GROUP 1635

TECH CENTER 1600 2900
MAR 26 2003

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)


FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
SEB	1	Branch, A. D. 1998. A good antisense molecule is hard to find. <i>TIBS</i> , 23:45-50.
	2	Dove, A. 2002. Antisense and sensibility. <i>Nature Biotechnology</i> , 20:121-124.
	3	Gucev, et al. 1996. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor β 2-induced growth inhibition in human breast cancer cells. <i>Cancer Research</i> , 56(7):1545-1550.
	4	Lebedeva, et al. 2001. Antisense oligonucleotides: Promise and reality. <i>Annu. Rev. Pharmacol. Toxicol.</i> , 41:403-419.
SW	5	Sofia, et al. *Analysis of the <i>Escherichia coli</i> genome. V. DNA sequence of the region from 76.0 to 81.5 minutes. Database accession no. XP-002228916.

S:\DOCS\DOH\DOH-7348.DOC:dmb
031803

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>9/15/03</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

#16

 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. ELITRA.011A	APPLICATION NO. 09/815,242
	APPLICANT Haselbeck, et al.	
	FILING DATE March 21, 2001	GROUP 1831 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

RECEIVED

APR 15 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
<i>RL</i>	1 Bennett, F. C. 1998. Antisense oligonucleotides: Is the glass half full or half empty? <i>Biochemical Pharmacology</i> , 55:9-19.
<i>RL</i>	2 Crooke, S. T. 1998. An overview of progress in antisense therapeutics. <i>Antisense & Nucleic Acid Drug Development</i> , 8:115-122.
<i>RL</i>	3 Gura, T. 1995. Antisense has growing pains. <i>Science</i> , 270:575-577.

S:\DOCS\DOH\DOH-7387.DOC:dmb
032603

EXAMINER <i>Russell</i>	DATE CONSIDERED 9/15/03
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	